Overview

Scopolamine Challenge Study

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive impairments in healthy adults subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Butylscopolammonium Bromide
Donepezil
Scopolamine
Scopolamine Hydrobromide